Developed for chronic hepatitis b to target viral replication and support liver health maintenance.
Mechanism of Action
Entecavir is a guanosine nucleoside analogue that inhibits Hepatitis B virus (HBV) polymerase. It specifically interferes with viral DNA priming, reverse transcription of the negative strand, and synthesis of the positive strand of viral DNA.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
12–15 hours (half-life)
Contraindications
Hypersensitivity to entecavir
Severe Adverse Events
Lactic acidosis, Severe hepatomegaly, Post-treatment hepatitis exacerbation — requires immediate medical attention
Common Side Effects
Headache, Fatigue, Dizziness
Uncommon Side Effects
Nausea, Insomnia, Abdominal pain
Drug Interactions
Alcohol, Ganciclovir, Acyclovir
Pregnancy Safety Warnings
FDA Category C: Benefit must justify risk. Breastfeeding: Not known if excreted in milk.
Age Restrictions
Safety and efficacy established in pediatric patients two years and older.
Storage Guidelines
Store at room temperature in original container, protected from light.
Information related to Baraclude is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
